Cargando…

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)

BACKGROUND: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive organisms, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. New onset or worsening renal impairment was observed in phase 3 clinical trials. This analysis w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassoun, Ali, Sundareshan, Vidya, Lacy, Melinda, Barnes, Chris, Castaneda-Ruiz, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255214/ http://dx.doi.org/10.1093/ofid/ofy210.2017

Ejemplares similares

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials
por: Nogid, Boris, et al.
Publicado: (2018)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
por: Polyzos, Konstantinos A., et al.
Publicado: (2012)

Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions
por: Gu, Zhengtian, et al.
Publicado: (2015)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?
por: Chuan, Junlan, et al.
Publicado: (2016)

Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
por: Rodriguez, George D, et al.
Publicado: (2017)

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
por: Bradley, John S., et al.
Publicado: (2023)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method
por: Ross, James E., et al.
Publicado: (2014)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
por: Roch, Melanie, et al.
Publicado: (2018)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus
por: Rajamuthiah, Rajmohan, et al.
Publicado: (2015)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus
por: Yim, Juwon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qleb23l497eps2v9pckpnasnks